Trial Profile
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 08 Feb 2024
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary) ; Nadunolimab (Primary) ; Pamrevlumab (Primary) ; Pelareorep (Primary) ; Racemetyrosine (Primary) ; Spartalizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Methoxsalen; Oxaliplatin; Paclitaxel; Phenytoin; Sirolimus
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms PanCAN-Precision-PromiseSM; Precision Promise
- 05 Feb 2024 According to a FibroGen media release, company announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM ET to include information on the mechanism of action of pamrevlumab in Phase 1/2 trial, Precision Promise Phase 2/3 trial and LAPIS Phase 3 trial.
- 25 Jan 2024 According to a FibroGen media release, Pamrevlumab is the first experimental arm to meet its required threshold for graduation in the seamless Phase 2/3 adaptive platform trial and pamrevlumab arm of the study completed Stage 2 of the trial in January 2024.
- 25 Jan 2024 According to a FibroGen media release, company announced graduation and completion of the pamrevlumab experimental arm. Topline data from this registration study is anticipated in the second quarter of 2024.